Quantification of α-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson's disease?

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Mollenhauer, Brit ^a,b  

^a Center of Parkinsonism and Movement Disorders   (Germany)

^b University Medical Center   (Germany)

Author keywords

Synuclein; Biomarker; Cerebrospinal fluid; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CORTICOBASAL DEGENERATION; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PROCESSING; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

BIOMARKER; CEREBROSPINAL FLUID; PARKINSON'S DISEASE; Α-SYNUCLEIN;

ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; HUMANS; PARKINSON DISEASE;

EID: 84887862096     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70020-8     Document Type: Article

References (30)

1. Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol 2005, 57:197-203.
2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
3. Spillantini MG, Goedert M The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 2000, 920:16-27.
4. Farrer MJ Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006, 7:306-318.
5. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010, 4:683-699.
6. Trojanowski JQ, Growdon JH A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research. J Neuropathol Exp Neurol 1998, 57:643-644.
7. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512-519.
8. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005, 65:1863-1872.
9. Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005, 57:82-91.
10. Schulz-Schaeffer WJ Neurodegeneration in Parkinson disease: moving Lewy bodies out of focus. Neurology 2012, 79:2298-2299.
11. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011, 10:230-240.
12. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
14. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013 Aug 26, [Epub ahead of print].
15. Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012, 69:1445-1452.
16. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012, 33:430. e1-3.
17. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011, 26:1428-1435.
18. Schmid AW, Fauvet B, Moniatte M, Lashuel HA Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson's disease and other synucleinopathies. Mol Cell Proteomics 2013 Aug 23, [Epub ahead of print].
19. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008, 213:315-325.
20. Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A, Lange P, et al. α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm 2012, 119:739-746.
21. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
22. Shi M, Sui YT, Peskind ER, Li GG, Hwang H, Devic I, et al. Salivary tau species are potential biomarkers of Alzheimer's disease. J Alzheimers Dis 2011, 27(2):299-305.
23. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011, 134:e178.
24. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A 2008, 105:10907-10912.
25. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010, 119:703-713.
26. Bolner A, Pilleri M, De Riva V, Nordera GP Plasma and urinary HPLC-ED determination of the ratio of 8-OHdG/2-dG in Parkinson's disease. Clin Lab 2011, 57:859-866.
27. Mattsson N, Blennow K, Zetterberg H Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med 2010, 48:603-607.
28. Iranzo A, Serradell M, Vilaseca I, Valldeoriola F, Salamero M, Molina C, et al. Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 2013, 19:600-604.
29. Shi M, Furay AR, Sossi V, Aasly JO, Armaly J, Wang Y, et al. DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging 2012, 33:836.e5-836.e7.
30. Mollenhauer B, Trautmann E, Sixel-Döring F, Wicke T, Ebentheuer J, Schaumburg M, et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 2013, 81:1226-1234.